Capitolis Achieves Record-Breaking 2025 Across Portfolio Optimization Business January 16, 2026 Company delivered record performance across FX, Rates, and Credit products and launched innovative offerings
Kolibri Global Energy Inc. Provides Operations Update January 16, 2026 Kolibri Global Energy Inc. (the “Company” or “Kolibri”) (TSX: KEI, NASDAQ: KGEI) is pleased to provide an operations update on its latest wells in its Tishomingo field in Oklahoma. BARNES WELLS The Barnes 6-31-2H and Barnes 6-4H wells (both 100% working interest) have been on production for approximately 30 days. The 1.5 mile lateral Barnes [...]
Amedeo Announces the Successful Conclusion and Capital Redemption of its LSE Listed Fund, “DNA3” January 16, 2026 Amedeo Limited (“Amedeo”) is pleased to announce the issuance of a compulsory redemption of shares and return of capital to the investors in DNA3 (the “Fund”), following Amedeo’s successful sale of four (4) Airbus A380-861 aircraft to Emirates during the third and fourth quarters of 2025. This milestone represents the culmination of a 12-year investment [...]
Whitbread offloads £89m worth of Premier Inns to Londonmetric January 13, 2026 Hospitality giant Whitbread has offloaded a number of its Premier Inn hotels to property group Londonmetric for £89m as it looks to boost profits. The group sold nine South Eastern hotels to the group, ranging from Southampton Airport to Warwick, as part of its plan to reuse £250m-£300m of property proceeds for growth opportunities, including [...]
London homeowners most likely to make a loss upon selling their home January 12, 2026 London homeowners are most likely to make a loss upon selling their house as prices in the capital continue to drop. In 2025, nearly 15 per cent of Londoners sold their home for less than they bought it, the highest proportion in England and Wales, according to analysis from real estate agent Hamptons, well above [...]
Terra Firma Energy Highlights the Critical Role of Flexible Generation in Securing the UK Power System January 8, 2026 Terra Firma Energy today reaffirmed the essential role that flexible generation plays in maintaining the stability, resilience, and affordability of the UK electricity system as renewable penetration continues to accelerate. Recent industry analysis and project developments across the UK energy sector underline a growing consensus: as nuclear capacity remains constrained, fast-responding flexible generation is indispensable [...]
OneSource Virtual Announces Strategic, Majority Growth Investment from TA January 7, 2026 OneSource Virtual (OSV), a leading provider of HR and payments services for the Workday ecosystem, today announced a strategic, majority growth investment from TA Associates (TA), a leading global private equity firm. This investment will support the continuation of OSV’s organic growth, product innovation, and enhanced customer capabilities across the Workday ecosystem. This press release [...]
Loomis Sayles Proudly Celebrates 100 Years of Client Commitment and Investment Excellence January 6, 2026 Loomis, Sayles & Company, the investment manager with $425 billion in assets under managementi, proudly marks its centennial year, celebrating a legacy of independent thinking and a relentless commitment to helping clients achieve their goals. Founded in January 1926, Loomis Sayles has grown to serving over 1,000 institutional clients in 28 countries offering differentiated investment [...]
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq January 5, 2026 Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.
Prometheus Group Expands Commitment to Environmental Health and Safety with NiSoft Acquisition December 23, 2025 Combines Best-in-Class Digital Permitting and Safety Solutions for Asset-Intensive Industries
